Global advances in omics technologies enable future drug discovery and growth opportunities
For a long time, drug discovery followed the same path and used conventional analytical methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development.
New York, 16 Feb. Feb. 2, 2022 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of “Global Advances in Omics Technologies Enable Future Drug Discovery and Growth Opportunities” Report – https://www.reportlinker.com/p06229449/?utm_source=GNW
Personalized therapy is on the rise and promises to be more effective and efficient in meeting challenges. With growing interest in personalized and precision medicine, drug development is an area of focus for pharmaceutical players, organizations regulators and ordinary people.
The existing scenario of one drug for one disease and all patient populations in the category is no longer suitable. The integration of the latest science and technology will enhance knowledge from traditional drug discovery and take pharmaceutical discovery to the next level.
Omics provides granular information that was nearly impossible to obtain and understand in the past, offering data on gene expression, patient cohort, and predictive drug response for proposed drugs. Developments in omics and AI also enable the visualization of disease-drug models. Omics allows researchers to study different parameters and combine information obtained from genomics, proteomics and metabolomics, which guide drug development decisions. Other types of omics technologies such as glycomics and lipidomics are growing, deepening researchers’ understanding of complex and interconnected biological pathways.
Read the full report: https://www.reportlinker.com/p06229449/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001